Myeloma Minute: Be a #myelomawarrior

myelomaMinBannerTemplate9.6.18.png

| ACTION | Be a Myeloma Warrior

540x270MAMBannerV2.jpg

Kick Off Myeloma Action Month with Us Tomorrow, March 1st

This year’s Myeloma Action Month (MAM), beginning March 1, 2019, focuses on Myeloma Warriors. The IMF is asking individuals like YOU to spread multiple myeloma awareness on a global scale. Here’s how:

We cannot wait to see all the ways in which you TAKE ACTION to increase myeloma awareness!

LearnMoreButton.png

| INNOVATION | Latest Research

540x270Darzalex.jpg

Subcutaneous Daratumumab Meets Primary Endpoints in Study

On February 25, 2019, Genmab A/S, the developer and manufacturer of Darzalex (daratumumab), announced topline results of the phase III COLUMBA study of subcutaneous (SC) daratumumab versus intravenous (IV) daratumumab for patients with relapsed or refractory myeloma. According to AP News, “the results showed that SC administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 is non-inferior to IV administration of daratumumab with regard to the co-primary end points of overall response rate (ORR) and Maximum Trough concentration (Ctrough) of daratumumab on day 1 of the third treatment cycle.” Not only was the safety profile similar, but patients who had SC daratumumab actually had slightly improved response rates compared to those who received it by intravenous infusion.

LearnMoreButton.png

| EDUCATION | Workshop

250s250sdrcw.jpg

| ACTION | Award Applications

250x250grants.jpg

Register Now for a Regional Community Workshop in La Jolla, California
Attention Myeloma Researchers! Funding Opportunity

The IMF will host a Regional Community Workshop at the San Diego Marriot (4240 La Jolla Village Dr.) in La Jolla, CA, on Saturday, March 23, 2019. Registration is FREE, but seating is limited. Learn from and meet one-on-one with myeloma experts Caitlin Costello, MD (UCSD/Sharp Healthcare Transplant Program, San Diego, CA), David H. Vesole, MD, PhD (John Theurer Cancer Center, Hackensack, NJ), and Deborah Doss RN, OCN (Dana-Farber Cancer Institute, Boston, MA).

The Department of Defense’s Peer Reviewed Cancer Research Program has released pre-announcements for researchers to have ample time to prepare their applications for funding. Myeloma researchers are eligible for this funding due to IMF’s advocacy on Capitol Hill to ensure blood cancers would remain as a topic area under the program for FY 2019. Review the pre-announcement at the link below. You can also reach out to advocacy@myeloma.org if you have any questions.

Register Now Button.png

LearnMoreButton.png

| INSPIRATION | Fundraiser

540x270running.jpg

Register Now for Myeloma Miracles 2019 Walk in Southern California

Two Southern California support groups — the Inland Empire and Inland Valley Warriors — are walking to raise money for the International Myeloma Foundation’s research and education initiatives. If you are in the area, join the First Annual Walk for Myeloma Miracles fundraiser at Central Park (11200 Base Line Rd), in Rancho Cucamonga, California, on March 9, 2019, at 9 a.m. PST. Sign up as an individual or as a team.

Register Now Button.png

| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series

DurieVideoBox2.28.19v2.jpg

CLINICAL TRIALS
EVENTS

New isatuximab Clinical Trial: the IMROZ Study

New isatuximab Clinical Trial: the IKEMA Study

Join the conversation about myeloma on the Smart Patients Message Board

March 15-16, 2019
IMF Patient & Family Seminar
Boca Raton, FL

March 23, 2019
Regional Community Workshop
La Jolla, CA

April 5-6, 2019
IMF Patient & Family Seminar
Short Hills, NJ

April 6, 2019
Regional Community Workshop
Seattle, WA

April 27, 2019
2019 Miles for Myeloma 5K Run/Walk
Philadelphia, PA

May 11, 2019
Regional Community Workshop
Edina, MN

subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Sanofi-Genzyme, and Takeda Oncology
and individuals like you who supported the IMF this year

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.